https://www.selleckchem.com/pr....oducts/ITF2357(Givin
Carfilzomib users were at higher risk of new-onset edema (HR 5.09, p less then 0.0001), syncope (HR 4.27, p less then 0.0001), dyspnea (HR 1.33, p less then 0.0001), and chest pain (HR 1.18, p less then 0.0001) as compared to carfilzomib nonusers. Age above 75 years, preexisting cardiovascular disease, obesity, and twice a week carfilzomib schedule were significant risk factors associated with cardiovascular adverse events in carfilzomib users. The median time of the onset for all cardiovascular adverse events was 3.1 months
Like
Comment
Share
